After results this week from @boulware_dr showing no benefit from hydroxychloroquine given as post-exposure prophylaxis, now similarly disappointing results from UK’s Recovery trial using it for treatment and the drug has been pulled from that trial.
bbc.com/news/health-52…
bbc.com/news/health-52…
@boulware_dr Question now is how other ongoing trials (like @WHO’s Solidarity trials) will react. But it sure looks like we are getting very close to the end of the hydroxychloroquine saga. Here’s hoping it will free up researchers to concentrate on more promising drugs.
@boulware_dr @WHO In a statement the chief investigators of the Recovery trial said 1542 patients had been randomized to hydroxychloroquine in the trial. They compared their outcomes with those of 3132 patients randomised to usual care alone. They found:
@boulware_dr @WHO "no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes."
@boulware_dr @WHO Important now that full data is published and scrutinized. But given prior skepticism about hydroxychloroquine and other results so far, it sure looks like the world will soon be moving on to the next “wonder drug”…
